A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study
Authors:
- William E. BradyWBWilliam E. Brady
- Stephen B. HowellSHStephen B. Howell
- Heather A. LankesHLHeather A. Lankes
- Russell J. SchilderRSRussell J. Schilder
- Susan M. ChristnerSCSusan M. Christner
- Sandra StrychorSSSandra Strychor
- Matthew A. PowellMPMatthew A. Powell
- Andrea R. HagemannAHAndrea R. Hagemann
- Kathleen N. MooreKMKathleen N. Moore
- Joan L. WalkerJWJoan L. Walker
- 1 May 2017
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 145 (2) , 236-242
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute (U10 CA180822, U10CA 180868)
This publication has 25 references indexed in Scilit:
- Tumor platinum concentration following intraperitoneal administration of cisplatin versus carboplatin in an ovarian cancer modelGynecologic Oncology, 2009
- Enhanced Delivery of Cisplatin to Intraperitoneal Ovarian Carcinomas Mediated by the Effects of Bortezomib on the Human Copper Transporter 1Clinical Cancer Research, 2009
- Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: A prospective, multicenter, open-label, randomized, two-way crossover drug—drug interaction studyClinical Therapeutics, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Intraperitoneal chemotherapy in the first‐line treatment of women with stage III epithelial ovarian cancerCancer, 2007
- Intraperitoneal Cisplatin and Paclitaxel in Ovarian CancerNew England Journal of Medicine, 2006
- Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: A Gynecologic Oncology Group StudyGynecologic Oncology, 2006
- Phase I Trial of Bortezomib and Carboplatin in Recurrent Ovarian or Primary Peritoneal CancerJournal of Clinical Oncology, 2005
- A phase 2 study of two doses of bortezomib in relapsed or refractory myelomaBritish Journal of Haematology, 2004
- A Phase 2 Study of Bortezomib in Relapsed, Refractory MyelomaNew England Journal of Medicine, 2003